期刊文献+

HIV-1侵入抑制剂的研究进展

Research progress on HIV-1 entry inhibitors
原文传递
导出
摘要 人类免疫缺陷病毒(HIV)-1侵入抑制剂能抑制HIV进入靶细胞,在最初环节抑制病毒的传播。具有高活性、较好药物代谢性质的肽及肽类似物不断被发现,并成为抗HIV药物研究的热点。根据HIV-1进入靶细胞的3个步骤可将侵入抑制剂分为黏附抑制剂、辅助受体结合抑制剂和融合抑制剂,并对其研发策略和研究进展进行综述。 Human immunodeficiency virus(HIV)-1 entry inhibitors can inhibit HIV entering the target cells, and restrain the spreading of virus at the first part. Peptide and peptide analogue with high activity, good metabolic characteristics continue to be discovered, and they become the research hot spot of anti-HIV drugs. According to three steps of HIV-1 into the target cells, HIV-1 entry inhibitors are divided into adhesion antagonists, auxiliary receptor inhibitors, and fusion inhibitors. Research strategies and recent insights of those peptides as well as their analogs are summarized.
出处 《现代药物与临床》 CAS 2015年第7期903-907,共5页 Drugs & Clinic
基金 黑龙江省教育厅科学技术研究项目(12521200) 哈尔滨医科大学药学院大学生创新基金项目
关键词 人类免疫缺陷病毒 侵入抑制剂 融合抑制剂 活性肽 肽类似物 human immunodeficiency virus entry inhibitors fusion inhibitors peptide peptide analogue
  • 相关文献

参考文献36

  • 1Eckert D M,Kim P S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region[J].Proc Natl Acad Sci U S A,2001,98(20): 11187-11192.
  • 2Ingallinella P,Bianchi E,Ladwa N A,et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency[J].Proc Natl Acad Sci U S A,2009,106(14): 5801-5806.
  • 3White J M,Delos S E,Brecher M,et al. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme[J].Crit Rev Biochem Mol Biol,2008,43(3): 189-219.
  • 4Bastian A R,Contarino M,Bailey L D,et al. Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions[J].Retrovirology,2013,10: 153.
  • 5Wu Z,Cocchi F,Gentles D,et al. Human neutrophil alpha-defensin 4 inhibits HIV-1 infection in vitro[J].FEBS Lett,2005,579(1): 162-166.
  • 6Mackewicz C E,Yuan J,Tran P,et al. alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors[J].AIDS,2003,17(14): F23-32.
  • 7Wang W,Owen S M,Rudolph D L,et al. Activity of alpha- and theta-defensins against primary isolates of HIV-1[J].J Immunol,2004,173(1): 515-520.
  • 8Chang T L,Francois F,Mosoian A,et al. CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition[J]. J Virol,2003,77(12): 6777-6784.
  • 9Gro? A,Brox R,Damm D,et al. Ligand selectivity of a synthetic CXCR4 mimetic peptide[J].Bioorg Med Chem,2015,23(14): 4050-4055.
  • 10Crublet E,Andrieu J P,Vives R R,et al. The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains,including the co-receptor binding site[J]. J Biol Chem,2008,283(22): 15193-15200.

二级参考文献46

  • 1DE-YULIU,JIAN-TAOYE,WEN-HUIYANG,JINYAN,CHANG-HONGZENG,SAZENG.Ampelopsin, a Small Molecule Inhibitor of HIV-1 Infection Targeting HIV Entry[J].Biomedical and Environmental Sciences,2004,17(2):153-164. 被引量:13
  • 2陈屏,杨峻山.蒲葵籽化学成分研究[J].中草药,2007,38(5):665-667. 被引量:8
  • 3Greene WC, Debyser Z, Ikeda Y, et al. Novel targets for HIV therapy[J]. Antiviral Res, 2008, 80 (3): 251-265.
  • 4Debnath AK. Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-1 [J]. Expert Opin Investig Drugs, 2006, 15 (5): 465-478.
  • 5Cooley LA, Lewin SR. HIV-1 cell entry and advances in viral entry inhibitor therapy [J]. J Clin Virol, 2003, 26 (2).. 121-132.
  • 6Zahn RC, Hennann FG, Kim EY, et aL Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides [J]. Gene Ther, 2008, 15 (17): 1210-1222.
  • 7Root MJ, Steger HK. HIV-1 gp41 as a Target for Viral Entry Inhibition [J]. Current Pharmaceutical Design, 2004, 10 (15) : 1805-1825.
  • 8Prineen K, Schols D. HIV chemokine receptor inhibitors as novel anti-HIV drugs [J]. Cytokine & Growth Factor Review, 2005, 16 (6) : 659-677.
  • 9Liu SW, Jiang SB. High Throughput Screening and Characterization of HIV-1 Entry Inhibitors Targeting gp41: Theories and Techniques [J]. Current Pharmaceutical Design, 2004, 10 (15) :1827-1843.
  • 10Shuwen L, Hong L, Jinkui N, et al. Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120 [J ]. J BiolChem, 2005, 280 (12): 11259-11273.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部